VIVUS Inc. is Today's Focus Stock on MicroStockProfit

/ Source: GlobeNewswire

DALLAS, May 4, 2011 (GLOBE NEWSWIRE) -- announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at:

VIVUS Inc. (VVUS) is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, obstructive sleep apnea and sexual health. Its lead product in clinical development, QNEXA, completed phase III clinical trials for the treatment of obesity currently being considered for approval by U.S. and EU regulators. QNEXA is also in phase II clinical trials for type II diabetes and obstructive sleep apnea. VVUS is also developing an erectile dysfunction drug, Avanafil, that is in phase III clinical trials.

This newsletter has been helping traders make great investment decisions on VVUS; click here for a 25% discount offer.

In the report, the analyst notes:

"For the first quarter ended March 31, 2011, VVUS reported a net loss of $9.9 million or $0.12 per share as compared to a net loss of $18.8 million or $0.23 per share for the first quarter of 2010. On average, analysts polled by Thomson Reuters expected a loss of $0.15 per share."

"VVUS intends to resubmit an application for regulatory approval of its long-delayed weight-loss drug QNEXA in the fourth quarter. The Company's resubmission of QNEXA to the U.S. FDA would have a limited indication to include only men and women of non-child bearing potential."

To read the entire report visit:

See what investors are saying about VVUS at

Get breaking news on VVUS at is a small-cap research and investment commentary provider. strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: Disclosure is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. is a Web site wholly owned by BlueWave Advisors, LLC. Neither nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT: Brian Johnson 1-888-307-2850